Compare Ally Financial Inc (ALLY) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ally Financial Inc vs BioNano Genomics Inc — how do they compare? Ally Financial Inc trades at $45.64 (market cap $13.97B), while BioNano Genomics Inc trades at $1.2 (market cap $13.77M). The key difference: Ally Financial Inc is far larger — about 1014.5× BioNano Genomics Inc's market cap, and Ally Financial Inc pays a 2.63% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| ALLY | BNGO | |
|---|---|---|
Market Cap | $13.97B | $13.77M |
Sector | Financials | Health |
52-Week High | $47.25 | $4.92 |
52-Week Low | $35.96 | $1.09 |
Dividend Yield | 2.63% | — |
Enterprise Value | — | $16.38M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $45.59, up 1.06% today, with a bearish technical signal but strong analyst support. The stock shows attractive valuation with a P/E of 11.07 and P/B of 1.05, supported by consistent earnings beats in recent quarters. Recent news highlights value potential and a strategic focus on auto lending and digital banking, with a dividend payment scheduled for May 2026.
The outlook is positive given the consensus price target of $55.25, implying significant upside. Risks include declining operating cash flow and macroeconomic pressures on net interest margins. The stock presents a value opportunity with disciplined capital return, but investors should monitor credit quality and interest rate sensitivity.
BNGO trades at $1.20, up 5.26% today, but technical signals are bearish with moving averages indicating selling pressure. The company reported a net loss of -$26.40M in 2025 despite beating EPS estimates in recent quarters. Recent news highlights leadership changes and growing adoption of its optical genome mapping technology, with 67% year-over-year growth in studies presented at ESHG 2026 (GlobeNewswire, June 18, 2026).
The outlook remains challenged by persistent losses and negative cash flow, though low valuation ratios (P/S 0.31, P/B 0.37) may attract value investors. Analyst sentiment is cautiously optimistic with 57% buy ratings, but execution risks and profitability concerns pose significant headwinds for near-term stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
